Efficacy and Safety of COVID-19 Vaccine in Cancer Patients

Overview

Información sobre este estudio

We hypothesize that cancer patients on cytotoxic chemotherapy which affect immune response may not mount adequate immune response to COVID-19 vaccines.

Aims, purpose, or objectives:

  1. To determine the antibody response to COVID-19 vaccine after vaccination.
  2. To assess the adverse events of COVID-19 vaccines in cancer patients.
  3. To determine the incidence and severity of COVID-19 infection after the vaccination.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Willing to receive COVID-19 vaccination as per standard of care or has already received one or both COVID-19 vaccine injections as long as it has not been longer than three months since their second injection (or the only injection if they receive the types of COVID-19 vaccines that do not require the second injection).
  • Willing and able to provide research blood samples.
  • Capable of providing valid informed consent.
  • For cancer patient cohort:
    • Male or female age ≥ 18 years;
    • Histologically confirmed solid malignancy on or will be starting on systemic cytotoxic chemotherapy.
  • For healthy individual cohort:
    1.  
    • Male or female age ≥ 18 years;
    • No history of active malignancy ≤ 3 years.
    • EXCEPTIONS: Adequately treated non-melanotic skin cancer (adequate wound healing is required prior to study entry) or carcinoma-in-situ of the cervix.
    • NOTE: If there is a history of prior solid tumor malignancy, it must have been treated curatively with no evidence of recurrence ≤ 3 years.

Exclusion Criteria:

  • Immunocompromised patients including patients known to be HIV positive or those on immunosuppressive therapy other than chemotherapy in the judgment of the investigator.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Jacksonville, Fla.

Investigador principal de Mayo Clinic

Saranya Chumsri, M.D.

Cerrado para la inscripción

Contact information:

Megan Skoglund

(904) 953-2120

Skoglund.Megan@mayo.edu

More information

Publicaciones

Publications are currently not available
.
CLS-20509687

Mayo Clinic Footer